Clinical trial CITADEL-205
A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kdelta Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Incyte Corporate |
| EudraCT Identifier | 2017-003148-19 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03235544 |
| Inclusion criteria | MCL - at least 1 but no more than 3 prior systemic treatment regimens |
| Last update |